(By accessing, browsing or using the pages below, you agree to the Blog Conditions of Use/Disclaimer available under "Links.")
On March 23, 2018, the federal omnibus spending bill was signed into law, which included an updated version of the Rohrabacher-Blumenauer Amendment prohibiting the use of DOJ funds for Controlled Substances Act enforcement in states with a medical cannabis program. READ MORE
On Thursday, March 22, the U.S. House of Representatives voted to approve the most recent omnibus spending bill, allocating the funds approved by President Trump when he signed a budget deal on February 8, 2018. READ MORE
Despite a recent setback for the cannabis industry at the federal level, an Illinois judge has ordered that intractable pain be added to the state's list of conditions approved for medical cannabis treatment, potentially widening the patient pool for cannabis. READ MORE
Today, just four days after recreational cannabis became legal in California – Attorney General Jeff Sessions rescinded the long-standing “Cole Memorandum” issued in 2013 by Deputy Attorney General James M. Cole. READ MORE
Thompson Coburn advises clients on state laws governing the business of cannabis to facilitate compliance with those state laws. Federal laws concerning cannabis currently conflict with state laws in states that have legalized cannabis or possession of cannabis. Although federal enforcement policy may at times defer to these states’ laws and not enforce conflicting federal laws, interested businesses and individuals should be aware that compliance with state law in no way assures compliance with federal law, and there is a risk that conflicting federal laws may be enforced in the future. In addition to this Cannabis-specific note, readers should review Thompson Coburn’s Conditions of Use / Disclaimers page containing other important information.
NOTICE.
Although we would like to hear from you, we cannot represent you until we know that
doing so will not create a conflict of interest. Also, we cannot treat unsolicited
information as confidential. Accordingly, please do not send us any information
about any matter that may involve you until you receive a written statement from
us that we represent you (an ‘engagement letter’).
By clicking the ‘ACCEPT’ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the ‘ACCEPT’ button if you understand and accept the foregoing statement and wish to proceed.
